medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2020, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2020; 18 (1)

Acquired Hyperpigmentations at Mexico General Hospital. Clinical-Pathological Correlation

Comonfort PTV, Arellano MMI, Mercadillo PP

Language: Spanish
References: 50
Page: 13-24
PDF size: 334.24 Kb.


ABSTRACT

Introduction: the acquired hyperpigmentations are benign skin diseases characterized by hyperchromic macules according to their etiology. They are also one of the main motives for dermatology consultation, therefore, is important to determine their etiology in order to choose the correct treatment.
Material and methods: a retrospective study was conducted with patient’s files that had undergone skin biopsy for their diagnosis. The files correspond to the Dermatology and Dermapathology Service at the Dr. Eduardo Liceaga General Hospital of Mexico. Sociodemographic data was collected and 265 patients were included. The clinical and histopathological diagnosis of acquired hyperpigmentation was verified as a referral reason.
Results: in 265 patients a 2:7 ratio male-female was observed; with a mean age of 50 years (±45 to 55 years); there were 49 different diagnosis, both clinical and histopathological; the more frequent clinical diagnosis (24.15%) was lichen planus pigmentosus and the histopathological findings were non-specific melanosis (20.75%): we also found that 66.03%, didn’t need a clinical-pathological correlation; never the less we found that 43% clinicians were accurate in their diagnosis.
Conclusion: the 57% of the acquired hyperpigmentations required a histopathological examination to corroborate the dermatologist’s clinical diagnosis, however in this cluster a different statistical analysis is required to establish if there is a statistical significance.


REFERENCES

  1. Kumarasinghe SPW, Pandya A, Chandran V et al., A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl’s melanosis, Int J Dermatol 2019;58(3):263-72.

  2. González N, Robles J y Ocampo J, Artículo de revisión: hiperpigmentaciones adquiridas, dcmq 2017; 16(1):50-62.

  3. Cestari TF, Dantas LP y Boza JC, Acquired hyperpigmentations, An Bras Dermatol 2014; 89(1):11-25.

  4. Wu Chang M, Hyperpigmentation disorders. En Bologna J, Jorizzo J y Schaffer J (eds.), Dermatology, Filadelfia, Elsevier Saunders, 2018, pp. 1115-43.

  5. Callender VD, St Surin-Lord S, Davis EC y Maclin M, Postinflammatory hyperpigmentation: etiologic and therapeutic considerations, Am J Clin Dermatol 2001; 12:87-99.

  6. Bandhlish A, Aggarwal A y Koranne R, A clinico-epidemiological study of macular amyloidosis from North India, Indian J Dermatol 2012; 57(4):269-74.

  7. Ogbechie-Godec OA y Elbuluk N, Melasma: an up-to-date comprehensive review, Dermatol Ther 2017; 7(3):305-18.

  8. Handel AC, Miot LDB y Miot HA, Melasma: a clinical and epidemiological review, Anais Brasileiros de Dermatologia 2014; 89(5):771-82.

  9. Arellano IM et al., Guías de diagnóstico y manejo de melasma, dcmq 2018; 16(1):12-23.

  10. Choubey V, Sarkar R, Garg V, Kaushik S, Ghunawat S y Sonthalia S, Role of oxidative stress in melasma: a prospective study on serum and blood markers of oxidative stress in melasma patients, Int J Dermatol 2017; 56(9):939-43.

  11. Lee A-Y, Recent progress in melasma pathogenesis, Pigment Cell Melanoma Res 2015; 28:648-60.

  12. Kwon S-H, Hwang Y-J, Lee S-K y Park K-C, Heterogeneous pathology of melasma and its clinical implications, Int J Mol Sci 2016; 17(6) pii: E824.

  13. Sánchez L, Liquen plano pigmentoso, Dermatol Perú 2010; 20(3):194-7.

  14. Kim EH, Kim YC, Lee E-S y Kang HY, The vascular characteristics of melasma, Journal of Dermatological Science 2007; 46(2):111-6.

  15. Bhutani L, Bedi T, Pandhi R y Nayak N, Lichen planus pigmentosus, Dermatologica 1974; 149(1):43-50.

  16. Bhutani L, George M y Bhate S, Vitamin A in the treatment of lichen planus pigmentosus, Br J Dermatol 1979; 4:473-4. TANIA VALERIA COMONFORT PLACIOS Y COLS. HIPERCROMIAS

  17. Shwartz RA, Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis, Int J Dermatol 2004; 43:230-2.

  18. Gao M, Wang PG, Yang S et al., Two frameshift mutations in the rnaspecific adenosine deaminase gene associated with dyschromatosis symmetrica hereditarian, Arch Dermatol 2005; 141:193-6.

  19. Muthu S, Narang T, Saika U, Kanwar A, Parsad D y Dogra S, Lowdose oral isotretinoin therapy in lichen planus pigmentosus: an openlabel non-randomized prospective pilot study, Int J Dermatol 2016; 55(9):1048-54.

  20. Silverberg NB, Herz J, Wagner A y Paller AS, Erythema dyschromicum perstans in prepubertal children, Pediatr Dermatol 2003; 20:398-403.

  21. Kanwar AJ, Dogra S, Parsad D y Radotra BD, A study of 124 Indian patients with lichen planus pigmentosus, Clin Exp Dermatol 2003; 28:481-5.

  22. Al-Mutairi N y El-Khalawany M, Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study, J Eur Acad Dermatol Venereol 2010; 24:535-40.

  23. Silpa-Archa N, Kohli I, Chaowattanapanit S, Lim H y Hamzavi I, Postinflammatory hyperpigmentation: a comprehensive overview, J Am Acad Dermatol 2017; 77(4):591-605.

  24. Kalter DC, Griffi WA y Atherton DJ, Linear and whorled nevoid hypermelanosis, J Am Acad Dermatol 1988; 19:1037-44.

  25. Zhang C, Li D, Zhang J et al., Mutations in abcb6 cause dyschromatosis universalis hereditarian, J Invest Dermatol 2013; 133:2221-8.

  26. Elston D y Ferringer T, Dermatopathology, vol. 2, Filadelfia, Elsevier, 2014.

  27. Savory S y Pandya A, Post-inflammatory hyperpigmentation. En Jackson R y Pandya AG (eds.), Dermatology atlas for skin of color, Berlín- Heidelberg, Springer, 2014, pp. 21-5.

  28. Ruiz R y Orozco M, Postinflamatory hypopigmentation and hyperpigmentation, Semin Cutan Med Surg 1997; 16(1):36-43.

  29. Miranda A, Frías A y Hierro S, Amiloidosis cutánea y su tratamiento, dcmq 2008; 6(1):29-34.

  30. Ferreira T, Pinheiro L y Catucci J, Acquired hyperpigmentations, An Bras Dermatol 2012; 89(1):11-25.

  31. Youssef M, Mokni S, Belhadjali H et al., Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation, Int J Clin Pharm 2013; 35:309-12.

  32. Sanz T, Córdoba S, Jiménez B y Borbujo J, 5-fluorouracil-induced reticular hyperpigmentation, Actas Dermosifilogr 2008; 99(7):573-82.

  33. Raulin C, Werner S y Greve B, Circumscripted pigmentations after iron injections: treatment with Q-switched laser, Lasers Surg Med 2001; 28:456-60.

  34. Cestari T, Arellano I, Hexsel D y Ortonne JP, Latin American Pigmentary Disorders Academy. Melasma in Latin America: options for therapy and treatment algorithm, J Eur Acad Dermatol Venereol 2009; 23:760-72.

  35. Cho HH, Choi M, Cho S y Lee JH Role of oral tranexamic acid in melasma patients treated with ipl and low fluence qs Nd:yag laser, J Dermatolog Treat 2013; 24:292-6.

  36. Hristov A, High W y Golitz L, Localized cutaneous argyria, J Am Acad Dermatol 2011; 65(3):660-1.

  37. Arellano I, Cestari T, Ocampo-Candiani J, Azulay-Abulafia L, Bezerra Trindade Neto P, Hexsel D et al., Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity, J Eur Acad Dermatol Venereol 2012; 26:611-8.

  38. Geria A, Tajirian A, Kihiczak G y Schwartz R, Minocycline-induced skin pigmentation: an update, Acta Dermatovenerol Croat 2009; 17(2):123-6.

  39. Taylor S, Grimes P, Lim J, Im S y Lui H, Postinflammatory hyperpigmentation, J Cutan Med Surg 2009; 13:183-91.

  40. Ritter CG, Fiss DV, Borges da Costa JA, De Carvalho RR, Bauermann G y Cestari TF, Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study, J Eur Acad Dermatol Venereol 2013; 27:1088-94.

  41. Taylor SC, Epidemiology of skin diseases in ethnic populations, Dermatol Clin 2003; 21:601-7.

  42. Achar A y Rathi SK, Melasma: a clinico-epidemiological study of 312 cases, Indian J Dermatol 2011; 56:380-2.

  43. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P et al., A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma, J Eur Acad Dermatol Venereol, 2009; 23:1254-62.

  44. Katz TM, Goldberg LH, Firoz BF y Friedman PM, Fractional photothermolysis for the treatment of post inflammatory hyperpigmentation, Dermatol Surg 2009; 35:1844-8.

  45. Cho SB, Park SJ, Kim JS, Kim MJ y Bu TS, Treatment of post-inflammatory hyperpigmentation using 1 064-nm Q-switched Nd:yag laser with low fluence: report of three cases, J Eur Acad Dermatol Venereol 2009; 23:1206-7.

  46. Polder KD, Landau JM, Vergilis-Kalner IJ, Goldberg LH, Friedman PM y Bruce S, Laser eradication of pigmented lesions: a review, Dermatol Surg 2011; 37:572-95.

  47. Chakrabarti N y Chattopadhyay C, Ashy dermatosis: a controversial entity, Indian J Dermatol 2012; 57:61-2.

  48. Combemale P, Faisant M, Guennoc B, Dupin M y Heyraud JD, Erythema dyschromicum perstans: report of a new case and critical review of the literature, J Dermatol 1998; 25:747-53.

  49. Torrelo A, Zaballos P, Colmenero I, Mediero IG, De Prada I y Zambrano A, Erythema dyschromicum perstans in children: a report of 14 cases, J Eur Acad Dermatol Venereol 2005; 19:422-6.

  50. Wang F, Zhao YK, Wang Z et al., Erythema dyschromicum perstans: response to isotretinoin, jama Dermatol 2016; 152: 841-2.




2020     |     www.medigraphic.com